Atypical hemolytic-uremic syndrome in pregnancy: a case report

Ridzki Hastanus Sembada, Lisyani Budipardigdo Suromo, M. Sofyan Harahap, Hardhono Susanto


Introduction: The diagnosis of Atypical hemolytic-uremic syndrome (aHUS) is largely imprecise. Improving outcomes requires accurate diagnosis and timely management. Acute kidney damage, thrombocytopenia, and microangiopathic hemolytic anemia are all signs of aHUS. The condition is brought on by pregnancy, and in genetically susceptible women, it progresses to a terrible hemolytic illness marked by widespread endothelium damage and platelet consumption. The sickness is a potentially fatal ailment that demands quick identification and treatment.

Case Presentation: Our facility provided treatment for severe anemia, thrombocytopenia, and acute renal damage in a 24-year-old G1P1A0 postpartum lady with Caesarean sectio and a HELLP syndrome suspicion. An aHUS diagnosis was later verified. The condition of the patient failed to improve in the first 24 hours after birth. Inside this presence of TMA, the patient began on daily TPE and ran in parallel prednisone medication (1 mg/kg/day). After six TPE cycles, the laboratory values began to rise.

Conclusion: AHUS can be challenging to diagnose early since it frequently mimics other illnesses. To enhance results, proper diagnosis and prompt management are essential. The management strategy includes a multidisciplinary team, early plasmapheresis, and complement inhibition. To lessen the effects of aHUS, TPE should be carried out as soon as feasible on a daily basis.


Atypical hemolytic-uremic syndrome; Pregnancy; Plasmapheresis; Therapy plasma exchange


Ardissino, G., Longhi, S., Porcaro, L., Pintarelli, G., Strumbo, B., Capone, V., Cresseri, D., Loffredo, G., Tel, F., Salardi, S., Sgarbanti, M., Martelli, L., Rodrigues, E. M., Borsa-Ghiringhelli, N., Montini, G., Seia, M., Cugno, M., Carfagna, F., Consonni, D., & Tedeschi, S. (2021). Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality. Kidney International Reports, 6(6), 1614–1621.

Bhandari, J., & Sedhai, Y. R. (2023). Hemolytic Uremic Syndrome. StatPearls Publishing.

Brocklebank, V., & Kavanagh, D. (2017). Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clinical Kidney Journal, 10(5), 600–624.

Bu, F., Borsa, N., Gianluigi, A., & Smith, R. J. H. (2012). Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clinical & Developmental Immunology, 2012, 370426.

Cofiell, R., Kukreja, A., Bedard, K., Yan, Y., Mickle, A. P., Ogawa, M., Bedrosian, C. L., & Faas, S. J. (2015). Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood, 125(21), 3253–3262.

Faguer, S., Huart, A., Fremeaux-Bacchi, V., Ribes, D., & Chauveau, D. (2013). Eculizumab and drug-induced haemolytic-uraemic syndrome. Clinical Kidney Journal, 6(5), 484–485.

Fakhouri, F., Roumenina, L., Provot, F., Sallée, M., Caillard, S., Couzi, L., Essig, M., Ribes, D., Dragon-Durey, M.-A., Bridoux, F., Rondeau, E., & Frémeaux-Bacchi, V. (2010). Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations. Journal of the American Society of Nephrology, 21(5), 859–867.

Feitz, W. J. C., van de Kar, N. C. A. J., Orth-Höller, D., van den Heuvel, L. P. J. W., & Licht, C. (2018). The genetics of atypical hemolytic uremic syndrome. Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik e.V, 30(4), 400–409.

Gurevich, E., & Landau, D. (2023). Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future. Pediatric Drugs, 25(2), 193–202.

Hans, R., Sharma, R. R., Marwaha, N., Suri, D., Kumar, R., Gupta, A., & Singh, S. (2016). Efficacy and safety of therapeutic plasma exchange by using apheresis devices in pediatric atypical hemolytic uremic syndrome patients. Journal of Clinical Apheresis, 31(4), 381–387.

Jokiranta, T. S. (2017). HUS and atypical HUS. Blood, 129(21), 2847–2856.

Le Clech, A., Simon-Tillaux, N., Provôt, F., Delmas, Y., Vieira-Martins, P., Limou, S., Halimi, J.-M., Le Quintrec, M., Lebourg, L., Grangé, S., Karras, A., Ribes, D., Jourde-Chiche, N., Rondeau, E., Frémeaux-Bacchi, V., & Fakhouri, F. (2019). Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney International, 95(6), 1443–1452.

Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., Karpman, D., Landau, D., Langman, C. B., Lapeyraque, A.-L., Licht, C., Nester, C., Pecoraro, C., Riedl, M., van de Kar, N. C. A. J., Van de Walle, J., … Frémeaux-Bacchi, V. (2016). An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 31(1), 15–39.

Loirat, C., & Frémeaux-Bacchi, V. (2011). Atypical hemolytic uremic syndrome. Orphanet Journal of Rare Diseases, 6(1), 60.

Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015). Complement System Part II: Role in Immunity. Frontiers in Immunology, 6.

Nester, C. M., Barbour, T., de Cordoba, S. R., Dragon-Durey, M. A., Fremeaux-Bacchi, V., Goodship, T. H. J., Kavanagh, D., Noris, M., Pickering, M., Sanchez-Corral, P., Skerka, C., Zipfel, P., & Smith, R. J. H. (2015). Atypical aHUS: State of the art. Molecular Immunology, 67(1), 31–42.

Noris, M., Bresin, E., Mele, C., & Remuzzi, G. (1993). Genetic Atypical Hemolytic-Uremic Syndrome.

Saad, A., Roman, J., Wyble, A., & Pacheco, L. (2016). Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome. American Journal of Perinatology Reports, 06(01), e125–e128.

Salvadori, M., & Bertoni, E. (2013). Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World Journal of Nephrology, 2(3), 56–76.

Schartz, N. D., & Tenner, A. J. (2020). The good, the bad, and the opportunities of the complement system in neurodegenerative disease. Journal of Neuroinflammation, 17(1), 354.

Schramm, E. C., Roumenina, L. T., Rybkine, T., Chauvet, S., Vieira-Martins, P., Hue, C., Maga, T., Valoti, E., Wilson, V., Jokiranta, S., Smith, R. J. H., Noris, M., Goodship, T., Atkinson, J. P., & Fremeaux-Bacchi, V. (2015). Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood, 125(15), 2359–2369.

Tomazos, I., Garlo, K., Wang, Y., Chen, P., & Laurence, J. (2020). Triggers in Patients with Atypical Hemolytic Uremic Syndrome: An Observational Cohort Study Using a US Claims Database. Blood, 136(Supplement 1), 30–31.

Vieira-Martins, P., El Sissy, C., Bordereau, P., Gruber, A., Rosain, J., & Fremeaux-Bacchi, V. (2016). Defining the genetics of thrombotic microangiopathies. Transfusion and Apheresis Science, 54(2), 212–219.

Walport, M. J. (2001). Complement. New England Journal of Medicine, 344(14), 1058–1066.

Waters, A. M., & Licht, C. (2011). aHUS caused by complement dysregulation: new therapies on the horizon. Pediatric Nephrology (Berlin, Germany), 26(1), 41–57.

Wong, E. K. S., Goodship, T. H. J., & Kavanagh, D. (2013). Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Molecular Immunology, 56(3), 199–212.

Yan, K., Desai, K., Gullapalli, L., Druyts, E., & Balijepalli, C. (2020). Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review. Clinical Epidemiology, Volume 12, 295–305.

Yoshida, Y., Kato, H., Ikeda, Y., & Nangaku, M. (2019). Pathogenesis of Atypical Hemolytic Uremic Syndrome. Journal of Atherosclerosis and Thrombosis, 26(2), 99–110.

Full Text: PDF

DOI: 10.24815/jks.v23i3.31485


  • There are currently no refbacks.